Pharmacokinetics and Pharmacodynamics of Inorganic Nitrate in Heart Failure With Preserved Ejection Fraction
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Rationale: Nitrate-rich beetroot juice has been shown to improve exercise capacity in heart failure with preserved ejection fraction, but studies using pharmacological preparations of inorganic nitrate are lacking. Objectives: To determine (1) the dose–response effect of potassium nitrate (KNO 3 ) on exercise capacity; (2) the population-specific pharmacokinetic and safety profile of KNO 3 in heart failure with preserved ejection fraction. Methods and Results: We randomized 12 subjects with heart failure with preserved ejection fraction to oral KNO 3 (n=9) or potassium chloride (n=3). Subjects received 6 mmol twice daily during week 1, followed by 6 mmol thrice daily during week 2. Supine cycle ergometry was performed at baseline (visit 1) and after each week (visits 2 and 3). Quality of life was assessed with the Kansas City Cardiomyopathy Questionnaire. The primary efficacy outcome, peak O 2 -uptake, did not significantly improve ( P =0.13). Exploratory outcomes included exercise duration and quality of life. Exercise duration increased significantly with KNO 3 (visit 1: 9.87, 95% confidence interval [CI] 9.31–10.43 minutes; visit 2: 10.73, 95% CI 10.13–11.33 minute; visit 3: 11.61, 95% CI 11.05–12.17 minutes; P =0.002). Improvements in the Kansas City Cardiomyopathy Questionnaire total symptom (visit 1: 58.0, 95% CI 52.5–63.5; visit 2: 66.8, 95% CI 61.3–72.3; visit 3: 70.8, 95% CI 65.3–76.3; P =0.016) and functional status scores (visit 1: 62.2, 95% CI 58.5–66.0; visit 2: 68.6, 95% CI 64.9–72.3; visit 3: 71.1, 95% CI 67.3–74.8; P =0.01) were seen after KNO 3 . Pronounced elevations in trough levels of nitric oxide metabolites occurred with KNO 3 (visit 2: 199.5, 95% CI 98.7–300.2 μmol/L; visit 3: 471.8, 95% CI 377.8–565.8 μmol/L) versus baseline (visit 1: 38.0, 95% CI 0.00–132.0 μmol/L; P <0.001). KNO 3 did not lead to clinically significant hypotension or methemoglobinemia. After 6 mmol of KNO 3 , systolic blood pressure was reduced by a maximum of 17.9 (95% CI −28.3 to −7.6) mm Hg 3.75 hours later. Peak nitric oxide metabolites concentrations were 259.3 (95% CI 176.2–342.4) μmol/L 3.5 hours after ingestion, and the median half-life was 73.0 (interquartile range 33.4–232.0) minutes. Conclusions: KNO 3 is potentially well tolerated and improves exercise duration and quality of life in heart failure with preserved ejection fraction. This study reinforces the efficacy of KNO 3 and suggests that larger randomized trials are warranted. Clinical Trial Registration : URL: http://www.clinicaltrials.gov . Unique identifier: NCT02256345
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography
Nagueh, S. F., Appleton, C. P., Gillebert, T. C., Marino, P. N., Oh, J. K., Smiseth, O. A., Waggoner, A. D., Flachskampf, F. A., Pellikka, P. A., & Evangelista, A. (2009) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2008.11.023 · Cited by 4,367
Recommendations for the evaluation of left ventricular diastolic function by echocardiography
Nagueh, S. F., Appleton, C. P., Gillebert, T. C., Marino, P. N., Oh, J. K., Smiseth, O. A., Waggoner, A. D., Flachskampf, F. A., Pellikka, P. A., & Evangelisa, A. (2008) · European Journal of Echocardiography · doi:10.1093/ejechocard/jep007 · Cited by 3,351 · cited 5×
“Inorganic nitrate supplementation improves muscle oxygenation, o(2) uptake kinetics, and exercise tolerance at high but not low pedal rates.”
InfluentialThe nitrate-nitrite-nitric oxide pathway in physiology and therapeutics
Lundberg, J. O., Weitzberg, E., & Gladwin, M. T. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2466 · Cited by 2,739
Green, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation
Cosby, K., Partovi, K. S., Crawford, J. H., Patel, R. P., Reiter, C. D., Martyr, S., Yang, B. K., Waclawiw, M. A., Zalos, G., Xu, X., et al. (2003) · Nature Medicine · doi:10.1038/nm954 · Cited by 1,807
Inorganic Nitrate Supplementation Lowers Blood Pressure in Humans: Role for Nitrite-Derived NO
Kapil, V., Milsom, A. B., Okorie, M., Maleki-Toyserkani, S., Akram, F., Rehman, F., Arghandawi, S., Pearl, V., Benjamin, N., Loukogeorgakis, S., et al. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.153536 · Cited by 621
Kapil, V., Khambata, R. S., Robertson, A., Caulfield, M. J., & Ahluwalia, A. (2015) · Hypertension · doi:10.1161/hypertensionaha.114.04675 · Cited by 500
Dietary Nitrate Supplementation and Exercise Performance
Jones, A. M. (2014) · Sports Medicine · doi:10.1007/s40279-014-0149-y · Cited by 442
Nitrite‐derived nitric oxide: a possible mediator of ‘acidic–metabolic’ vasodilation
Modin, A., Björne, H., Herulf, M., Alving, K., Weitzberg, E., & Lundberg, J. O. N. (2001) · Acta Physiologica Scandinavica · doi:10.1046/j.1365-201x.2001.00771.x · Cited by 346
Effect of Inorganic Nitrate on Exercise Capacity in Heart Failure With Preserved Ejection Fraction
Zamani, P., Rawat, D., Shiva-Kumar, P., Geraci, S., Bhuva, R., Konda, P., Doulias, P.-T., Ischiropoulos, H., Townsend, R. R., Margulies, K. B., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.012957 · Cited by 307
Self-citation
Cited by
Shah, S. J., Borlaug, B. A., Kitzman, D. W., McCulloch, A. D., Blaxall, B. C., Agarwal, R., Chirinos, J. A., Collins, S., Deo, R. C., Gladwin, M. T., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.041886 · Cited by 436
Ikonomidis, I., Aboyans, V., Blacher, J., Brodmann, M., Brutsaert, D. L., Chirinos, J. A., De Carlo, M., Delgado, V., Lancellotti, P., Lekakis, J., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1436 · Cited by 383
Self-citationBorlaug, B. A., Anstrom, K. J., Lewis, G. D., Shah, S. J., Levine, J. A., Koepp, G. A., Givertz, M. M., Felker, G. M., LeWinter, M. M., Mann, D. L., et al. (2018) · JAMA · doi:10.1001/jama.2018.14852 · Cited by 270
Self-citationEisman, A. S., Shah, R. V., Dhakal, B. P., Pappagianopoulos, P. P., Wooster, L., Bailey, C., Cunningham, T. F., Hardin, Baggish, A. L., Ho, J. E., et al. (2018) · Circulation: Heart Failure · doi:10.1161/circheartfailure.117.004750 · Cited by 259
Targeting obesity and diabetes to treat heart failure with preserved ejection fraction
Altara, R., Giordano, M., Nordén, E. S., Cataliotti, A., Kurdi, M., Bajestani, S. N., & Booz, G. W. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00160 · Cited by 61
Metadata
- Authors
- Zamani, P., Tan, V., Soto-Calderon, H., Beraun, M., Brandimarto, J. A., Trieu, L., Varakantam, S., Doulias, P.-T., Townsend, R. R., Chittams, J., Margulies, K. B., Cappola, T. P., Poole, D. C., Ischiropoulos, H., & Chirinos, J. A.
- Venue
- Circulation Research
- Published
- 2017-03-31
- Volume
- 120
- Issue
- 7
- Pages
- 1151-1161
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2559852365
- Cited by
- 61
- References
- 15
- FWCI
- 6.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetics and Pharmacodynamics of Inorganic Nitrate in Heart Failure With Preserved Ejection Fraction. https://app.cochat.ai/papers/10.1161/circresaha.116.309832
- The paper
- Zamani, P., Tan, V., Soto-Calderon, H., Beraun, M., Brandimarto, J. A., Trieu, L., Varakantam, S., Doulias, P.-T., Townsend, R. R., Chittams, J., Margulies, K. B., Cappola, T. P., Poole, D. C., Ischiropoulos, H., & Chirinos, J. A. (2017). Pharmacokinetics and Pharmacodynamics of Inorganic Nitrate in Heart Failure With Preserved Ejection Fraction. Circulation Research. https://doi.org/10.1161/circresaha.116.309832
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.